We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A long‐term course of alopecia areata during omalizumab treatment: a case report.
- Authors
Miyamoto, Manabu; Higano, Yuki; Yoshihara, Shigemi
- Abstract
This article discusses a case report of a 14-year-old girl who developed alopecia areata (AA) during treatment with omalizumab, a monoclonal anti-IgE antibody used for chronic spontaneous urticaria (CSU). The patient had a history of atopic dermatitis and seasonal allergic rhinitis and experienced increased urticaria frequency. Despite initial improvement with omalizumab, the patient developed AA after the fourth administration of the second course of treatment. However, the AA improved after six months and reoccurred three months after discontinuing omalizumab. The article suggests that the patient's atopic background may have contributed to the development of AA, and it emphasizes the importance of accurately determining the cause of symptoms in patients using antibody drugs.
- Subjects
ALOPECIA areata; OMALIZUMAB; URTICARIA; MONOCLONAL antibodies; ALLERGIC rhinitis; ATOPIC dermatitis
- Publication
International Journal of Dermatology, 2023, Vol 62, Issue 12, pe621
- ISSN
0011-9059
- Publication type
Article
- DOI
10.1111/ijd.16823